PRICING AND REIMBURSEMENT FRAMEWORKS IN CHINA, JAPAN AND SOUTH KOREA WITH FOCUS ON KEY REIMBURSEMENT DRIVERS

被引：0

作者：

Singh, B. ^{[1
]}

Sehgal, M. ^{[1
]}

机构：

[1] PAREXEL Int, Chandigarh, India

来源：

VALUE IN HEALTH | 2018年 / 21卷

关键词：

D O I：

10.1016/j.jval.2018.07.402

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PHP71

引用

页码：S53 / S53

页数：1

共 50 条

[1] Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement
Cho, Eun
Yoo, Seung-Lai
Kang, Youngju
Lee, Jong Hyuk
REGENERATIVE MEDICINE, 2020, 15 (04) : 1551 - 1560
[2] KEY DRIVERS FOR PRICING AND REIMBURSEMENT FOR BIOLOGIC DRUGS IN FRANCE
Niklitschek, T.
Williams, A. E.
Storer, M.
VALUE IN HEALTH, 2012, 15 (07) : A452 - A452
[3] Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
Lee, SungKyung
Lee, Jong Hyuk
FRONTIERS IN PUBLIC HEALTH, 2023, 11
[4] Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
Lee, Jong Hyuk
HEALTHCARE, 2021, 9 (03)
[5] Drug Reimbursement Decision-Making in Thailand, China, and South Korea
Ngorsuraches, Surachat
Meng, Wei
Kim, Bo-Yeon
Kulsomboon, Vithaya
VALUE IN HEALTH, 2012, 15 (01) : S120 - S125
[6] THE PRICING AND REIMBURSEMENT OF SPECIALTY DRUGS IN KEY ASIAN MARKETS
Subramanian, D.
Dummett, H.
VALUE IN HEALTH, 2016, 19 (07) : A817 - A817
[7] WHAT ARE THE KEY DRIVERS OF REIMBURSEMENT FOR BIOSIMILARS? AN EXAMINATION OF REIMBURSEMENT PROCESSES AND RECOMENDATIONS ACROSS NINE COUNTRIES
de Silva, S. U.
Smith, T. A.
Bending, M. W.
VALUE IN HEALTH, 2013, 16 (07) : A323 - A323
[8] THE ROLE OF ECONOMIC EVIDENCE IN DRUG REIMBURSEMENT: SOUTH KOREA
Bae, E.
Lee, H.
Kwon, H.
Yang, B.
VALUE IN HEALTH, 2016, 19 (07) : A826 - A826
[9] REVIEW OF PRICING AND REIMBURSEMENT SYSTEMS IN SOUTH-EASTERN EUROPE
Zibelnik, N.
Odeyemi, I. A.
VALUE IN HEALTH, 2014, 17 (07) : A429 - A429
[10] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
Lee, Jong Hyuk
Yoo, Seung-Lai
EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28

← 1 2 3 4 5 →